An Observational Study Into Antimicrobial Resistance in Patients With a Chronic Lung Disease

Starting soon

Conditions studied: Chronic Lung Diseases

In brief

Antimicrobial resistance (AMR) refers to the ability of microorganisms like bacteria, viruses, fungi and parasites to resist the effects of antimicrobial drugs (such as antibiotics) which are widely used as treatment. AMR poses an escalating global health threat, contributing to difficult-to-treat infections associated with increased disease spread, disability and death, as well as a substantial economic burden. In chronic lung diseases, such as bronchiectasis, Cystic fibrosis or chronic obstructive lung disease (COPD), there is a higher risk of AMR due to the exposure to frequent or prolonged courses of antibiotics to treat recurrent lung infections and exacerbations (flares of the disease), to reduce lung inflammation or to control chronic infection within the lung with suppression of colonising microbes. Most data on AMR in chronic lung diseases derive from analysing pre-existing routinely collected health data collected on a national basis which is often incomplete. Hence a prospective study is crucial to better understand and address AMR in chronic lung diseases. Prospective studies follow patients forward in time, collecting data on outcomes and allowing researcher to observe the natural history of AMR development, monitor trends and evaluate interventions. This multicentre prospective study, as part of the European Respiratory Society (ERS) Clinical Research Collaboration on Antimicrobial Resistance in Lung Disease (CRC - AMR Lung), aims to investigate the patterns of AMR in chronic lung diseases through a fully anonymous registry alongside a prospective sub-cohort study tracking individuals with chronic lung disease and known colonisation with high-priority AMR pathogens (microorganisms). This study will enable analysis of prevalence and burden of AMR within chronic lung disease alongside understand the genetic drivers of resistance, the link between the microbial genotype and antimicrobial resistance and how transmission of resistance occurs in chronic lung disease.

Key facts

Study ID

NCT07646691

Run by

Imperial College London

People needed

170

Starts

2026-07-01

Expected to finish

2028-12-01

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Presence of an underlying chronic lung disease (e.g. Bronchiectasis, COPD) stratified by colonisation status:
• Pseudomonas sp (n=30)
• Klebsiella sp (n=20)
• Haemophilus sp (n=20)
• E-coli sp (n=20)
• Stenotrophomonas sp (n=20)
• Staphylococcus sp (n=20)
• Other chronic colonisation (n=20)
• Not colonised with any bacterial pathogen (n=20)

You may not qualify if…

• Inability to provide informed consent
• Pregnancy
• Medical instability preventing ability to attend for regular study visits at baseline.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.